While Babcock & Brown had a lot of negative press last year, there has been remarkably little bad news of late and I believe all bad news is already factored into the share price. Babcock & Brown is now prime for a rebound. Their business model remains completely intact, they are developing and growing their business, and their is little risk of any further downside
SELL - Biota (BTA)
Sales forecasts for the swine flu vaccine appear ambitious given the viruss mild nature and the need for single shots rather than double. Coupled with public indifference, the take-up has been lower than expected in the UK and other countries. With uncertainty hanging over revenues, its time to take some profits and look elsewhere.
BTA Price at posting:
$2.04 Sentiment: Buy Disclosure: Held
